{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:45:27Z","timestamp":1792986327375,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton beam therapy is increasingly implemented for lower-grade gliomas worldwide, aiming to reduce radiation exposure to healthy tissue and lower treatment related toxicity. However, robust clinical evidence of the benefit of radiotherapy delivered with protons compared to photons is lacking. Importantly, although proton therapy offers potential benefits compared to photon radiotherapy, it is still ionizing radiation and can be associated with severe complications. Emerging concerns include a possible increase of radiotherapy-induced contrast-enhancing lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A healthy woman in her mid-forties underwent a subtotal resection for an\n                      <jats:italic>IDH-<\/jats:italic>\n                      mutated oligodendroglioma CNS WHO grade 2. She was randomized to proton therapy in the PRO-GLIO trial and received a dose of 54 Gray (Gy) relative biological effectiveness (RBE), followed by chemotherapy. Ten months after completion of radiotherapy, she reported rapid visual deterioration ultimately resulting in blindness. She also developed substantial cognitive deficits, pituitary and hypothalamic failure, and a general decline. MRI showed considerable, progressive radionecrosis in large parts of the irradiated brain. Tragically, the patient passed away 22 months after completing proton therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that although proton beam therapy is considered safe and potentially encumbered with fewer side effects than photon radiotherapy, serious complications may occur. Careful consideration of timing and execution of adjuvant therapy for lower-grade gliomas is essential. Randomized controlled trials are necessary to disclose if proton beam therapy is beneficial or not in lower-grade gliomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1803943","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:54Z","timestamp":1778219814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Proton beam therapy \u2013 friend or foe for patients with IDH-mutated WHO grade 2 and 3 gliomas?"],"prefix":"10.3389","volume":"16","author":[{"given":"Liv Cathrine","family":"Heggeb\u00f8","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Fredrik","family":"Fj\u00e6ra","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Leonel Bello","family":"Garrote","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Maria Henriksen","family":"Borgen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]},{"name":"Department of Physical Medicine and Rehabilitation, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Blakstad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taran Paulsen","family":"Hellebust","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrine","family":"Saxhaug","sequence":"additional","affiliation":[{"name":"Department of Radiology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Knutstad","sequence":"additional","affiliation":[{"name":"Department of Radiology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillevi","family":"Rylander","sequence":"additional","affiliation":[{"name":"The Skandion Clinic","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital","place":["Gothenburg, Sweden"]},{"name":"Department of Medical Radiation Science, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"The Skandion Clinic","place":["Uppsala, Sweden"]},{"name":"Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital","place":["Gothenburg, Sweden"]},{"name":"Department of Medical Radiation Science, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Werlenius","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg","place":["Gothenburg, Sweden"]},{"name":"Department of Oncology, Sahlgrenska University Hospital","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Blomstrand","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg","place":["Gothenburg, Sweden"]},{"name":"Department of Oncology, Sahlgrenska University Hospital","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/nejmoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104501","article-title":"Proton therapy for adult-type diffuse glioma: a systematic review","volume":"204","author":"Goliot","year":"2024","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.2002","article-title":"Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q codeletion: NCT00626990","volume":"43","author":"Bent","year":"2025","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-023-04368-6","article-title":"Long-term follow up of patients with WHO grade 2 oligodendroglioma","volume":"164","author":"Carstam","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2022.05.004","article-title":"Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma: an ASTRO clinical practice guideline","volume":"12","author":"Halasz","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/radiation1030019","article-title":"Proton therapy and gliomas: a systematic review","volume":"1","author":"Chambrelant","year":"2021","journal-title":"Radiation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00073","article-title":"Radiation-induced brain injury: a review","volume":"2","author":"Robbins","year":"2012","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01131-x","article-title":"Mitigating radiotoxicity in the central nervous system: role of proton therapy","volume":"24","author":"Winter","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190237","article-title":"Proton therapy for brain tumours in the area of evidence-based medicine","volume":"93","author":"Weber","year":"2020","journal-title":"Br J Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13014-025-02702-y","article-title":"Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study","volume":"20","author":"Goliot","year":"2025","journal-title":"Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"v102","DOI":"10.1093\/neuonc\/noaf201.0414","article-title":"RADT-45. The multicenter SOPRANO study: outcomes of patients with IDH-mutated WHO grade 2 and 3 glioma treated with proton or photon radiotherapy","volume":"27","author":"Nagtegaal","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110716","article-title":"Mixed effect model confirms increased risk of image changes with increasing linear energy transfer in proton therapy of gliomas","volume":"204","author":"Vestergaard","year":"2025","journal-title":"Radiotherapy Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070071","article-title":"Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden","volume":"13","author":"Heggeb\u00f8","year":"2023","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-097810","article-title":"APPROACH: Analysis of proton versus photon radiotherapy in oligodendroglioma and assessment of cognitive health - study protocol paper for a phase III multicentre, open-label randomised controlled trial","volume":"15","author":"Slevin","year":"2025","journal-title":"BMJ Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","article-title":"Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus","volume":"128","author":"Lambrecht","year":"2018","journal-title":"Radiotherapy Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-8140(02)00078-6","article-title":"Radiotherapy for newly diagnosed Malignant glioma in adults: a systematic review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiotherapy Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110401","article-title":"Dosimetric comparison of proton radiation therapy, volumetric modulated arc therapy, and three-dimensional conformal radiotherapy based on intracranial tumor location","volume":"10","author":"Adeberg","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.2910","article-title":"Addressing diffuse glioma as a systemic brain disease with single-cell analysis","volume":"69","author":"Sahm","year":"2012","journal-title":"Arch Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.2152","article-title":"NRG Oncology White Paper on the relative biological effectiveness in proton therapy","volume":"121","author":"Paganetti","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.12.035","article-title":"Radiation induced contrast enhancement after proton beam therapy in patients with low grade glioma \u2013 How safe are protons","volume":"167","author":"Harrabi","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"v19","DOI":"10.1093\/neuonc\/noae144.055","article-title":"OS05.7.A Radiation-induced contrast enhancement after proton therapy in patients with gliomas in the PRO-CNS study","volume":"26","author":"Werlenius","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-022-04217-y","article-title":"Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3","volume":"162","author":"Eichkorn","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.01.099","article-title":"Association of 1p\/19q codeletion and radiation necrosis in adult cranial gliomas after proton or photon therapy","volume":"101","author":"Acharya","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.08.025","article-title":"Iatrogenic influence on prognosis of radiation-induced contrast enhancements in patients with glioma WHO 1\u20133 following photon and proton radiotherapy","volume":"175","author":"Eichkorn","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109674","article-title":"Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma","volume":"184","author":"Jaspers","year":"2023","journal-title":"Radiotherapy Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2018.01.002","article-title":"Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma","volume":"9","author":"Bronk","year":"2018","journal-title":"Clin Trans Radiat Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-018-03063-1","article-title":"Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide","volume":"142","author":"Dworkin","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"225009","DOI":"10.1088\/1361-6560\/aae8a5","article-title":"LET-weighted doses effectively reduce biological variability in proton radiotherapy planning","volume":"63","author":"McMahon","year":"2018","journal-title":"Phys Med Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.03.013","article-title":"Late contrast enhancing brain lesions in proton-treated patients with low-grade glioma: clinical evidence for increased periventricular sensitivity and variable RBE","volume":"107","author":"Bahn","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100978","article-title":"Radiotherapy in Li-Fraumeni syndrome: from biological concern to personalized clinical decision-making","volume":"18","author":"El Mjabber","year":"2026","journal-title":"Cureus"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1753","article-title":"Radiation dose\u2013volume effects of optic nerves and chiasm","volume":"76","author":"Mayo","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1803943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:56Z","timestamp":1778219816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1803943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1803943"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1803943","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1803943"}}